PARIS–(BUSINESS WIRE)–Regulatory News: ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT) (Paris:ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, is announcing today the appointment of Patricia Zilliox as an independent director to replace Corinne Le Goff, whose plurality of […]
Author: Ken Dropiewski
Silence Therapeutics Appoints J.P. Gabriel as Chief Technical Operations Officer
LONDON–(BUSINESS WIRE)–Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), an experienced and innovative biotechnology company committed to transforming people’s lives by silencing diseases through precision engineered medicines, today announced the appointment of J.P. Gabriel as Chief Technical Operations Officer following the retirement of Jørgen Wittendorff, SVP, Technical Operations. In […]
My Cardiologist Launches The Women’s Heart Health Program
New program offers comprehensive prevention services, screenings, diagnostics and treatment for the number one cause of death and illness in all women MIAMI, Feb. 2, 2023 /PRNewswire/ — Novocardia, a value-based cardiovascular disease care platform, and My Cardiologist, a trusted provider of cardiovascular services in South Florida for more than 60 years, are pleased to announce the […]
TransMedics Appoints Nick Corcoran as Senior Vice President of Supply Chain and Operations
ANDOVER, Mass., Feb. 2, 2023 /PRNewswire/ — TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, announced today the appointment of Nick Corcoran as Senior Vice President of Supply Chain and Operations, effective immediately. “Nick has extensive end-to-end supply chain and […]
Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering
CHAPEL HILL, N.C., Feb. 03, 2023 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, announced today the pricing of a public offering of (i) 8,666,666 shares of its common […]
Integer Holdings Corporation Reduces Borrowing Costs with Closing of $500 million of Convertible Senior Notes Offering
~ Strategic transaction to meaningfully reduce interest expense ~ ~ Immediately earnings accretive in 2023 ~ PLANO, Texas, Feb. 03, 2023 (GLOBE NEWSWIRE) — Integer Holdings Corporation (NYSE: ITGR) (the “Company”), a leading medical device outsource manufacturer, announces the closing of its offering of $500 million aggregate principal amount of […]
HeartSciences Announces Further Internationalization of its Patent Portfolio
Granted Korean Patent for its MyoVista® Wavelet Technology Southlake, Texas, Feb. 03, 2023 (GLOBE NEWSWIRE) — Heart Test Laboratories, Inc. d/b/a HeartSciences (NASDAQ: HSCS; HSCSW) (“HeartSciences” or the “Company”), a medical technology company focused on saving lives by making an ECG (also known as an EKG) a far more valuable screening tool […]
Amarin Mails Letter to Shareholders Highlighting New Board and Superior Leadership
Significantly Refreshed Board Overseeing Successful Execution of Amarin’s Transformation Plan to Drive Short- and Long-Term Value; Outmatches Sarissa’s Slate in Every Critical Area Chairman Per Wold-Olsen Brings Critical Experience and Leadership Releases Additional Board Videos Available at www.voteamarin.com Urges Shareholders to Vote “AGAINST” Sarissa’s Proposals on the WHITE Proxy Card DUBLIN, […]
Morton Plant First in Florida to Participate in Trial to Expand TAVR to Aortic Regurgitation Patients
CLEARWATER, Fla., Feb. 1, 2023 /PRNewswire/ — The team at the Center for Advanced Valve and Structural Heart Care at BayCare’s Morton Plant Hospital achieved another first when they used the minimally invasive Transcatheter Aortic Valve Replacement (TAVR) procedure to treat a patient suffering from aortic regurgitation. The team led by Joshua Rovin, […]
BD Reports First Quarter Fiscal 2023 Financial Results
Execution of BD 2025 Strategy Delivering Consistent and Durable Performance Revenue of $4.6 billion decreased 2.8% as reported and increased 1.7% on a currency-neutral basis Revenue from base business (which excludes COVID-only diagnostic testing) grew 0.4% as reported, 5.2% currency-neutral GAAP and adjusted diluted EPS from continuing operations of $1.70 and $2.98, respectively Company raises […]



